Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Published on December 17, 2013 at 4:56 AM · No Comments

Agenus Inc. (NASDAQ: AGEN), a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced results published from a Phase 2 study demonstrated that more than 90% of the patients treated with Prophage Series G-200 were alive at six months after surgery and 30% were alive at twelve months. Additionally, the median overall survival was approximately eleven months. This compares favorably to the expected median survival for recurrent Glioblastoma multiforme (GBM) patients of three to nine months. The primary objective of this multi-center, single arm Phase 2 trial was to assess the survival rate at six months.

The data was published in a manuscript in Neuro-Oncology, the official journal of the Society of Neuro-Oncology. GBM is the most common and most aggressive form of primary brain cancer. Despite approved therapy patients with GBM face a poor prognosis. Prophage Series vaccines are currently being studied in both newly diagnosed and recurrent GBM.

"Glioblastoma tumors are often resistant to standard therapies and the extended survival observed in patients treated with Prophage Series vaccine is very promising," said Andrew Parsa, MD, PhD, corresponding author of the study and chair of neurological surgery at Northwestern Memorial Hospital and the Michael J. Marchese Professor and chair of the department of neurological surgery at the Feinberg School of Medicine at Northwestern University. "The next phase of development is underway with an NCI funded, large-scale, randomized trial investigating Prophage Series G-200 in combination with Avastin (bevacizumab). Avastin is approved for the treatment of recurrent GBM and we believe there is the potential for a synergistic effect of a targeted anti-tumor immunotherapy and anti-angiogenic agent that could benefit patients."

Prophage Series vaccines are individualized cancer vaccines. Each Prophage Series vaccine is manufactured using a patient's own tumor after surgical removal. Each vaccine contains the 'antigenic fingerprint' of the patient's particular cancer and is designed to activate the patient's immune system to specifically target and destroy cancer cells bearing this fingerprint.

Prophage Series G-200 Study Design

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post